- Home
- GAME vs PULM Comparison
GAME vs PULM Comparison
Compare GAME & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- PULM
- Stock Information
- Founded
- GAME 2011
- PULM 2003
- Country
- GAME United States
- PULM United States
- Employees
- GAME N/A
- PULM N/A
- Industry
- GAME
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- PULM Health Care
- Exchange
- GAME Nasdaq
- PULM Nasdaq
- Market Cap
- GAME 27.2M
- PULM 28.3M
- IPO Year
- GAME 2009
- PULM N/A
- Fundamental
- Price
- GAME $0.85
- PULM $8.89
- Analyst Decision
- GAME Strong Buy
- PULM
- Analyst Count
- GAME 3
- PULM 0
- Target Price
- GAME $3.67
- PULM N/A
- AVG Volume (30 Days)
- GAME 433.5K
- PULM 24.5K
- Earning Date
- GAME 05-15-2025
- PULM 05-15-2025
- Dividend Yield
- GAME N/A
- PULM N/A
- EPS Growth
- GAME N/A
- PULM N/A
- EPS
- GAME N/A
- PULM N/A
- Revenue
- GAME $99,579,536.00
- PULM $1,921,000.00
- Revenue This Year
- GAME $6.08
- PULM N/A
- Revenue Next Year
- GAME $21.94
- PULM $134.88
- P/E Ratio
- GAME N/A
- PULM N/A
- Revenue Growth
- GAME 77.06
- PULM N/A
- 52 Week Low
- GAME $0.50
- PULM $1.78
- 52 Week High
- GAME $1.43
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- GAME 58.35
- PULM 65.38
- Support Level
- GAME $0.86
- PULM $8.49
- Resistance Level
- GAME $0.92
- PULM $9.16
- Average True Range (ATR)
- GAME 0.07
- PULM 0.66
- MACD
- GAME 0.01
- PULM 0.18
- Stochastic Oscillator
- GAME 50.74
- PULM 85.32
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).